Disorders of glucose metabolism in patients infected with human immunodeficiency virus.
about
Adverse effects of antiretroviral therapy for HIV infectionIncreasing rates of obesity among HIV-infected persons during the HIV epidemicSoluble and cell-associated insulin receptor dysfunction correlates with severity of HAND in HIV-infected womenHIV-1 Vpr induces adipose dysfunction in vivo through reciprocal effects on PPAR/GR co-regulation.HIV pharmaceutical care in primary healthcare: Improvement in CD4 count and reduction in drug-related problemsImpact of pharmacist interventions on drug-related problems and laboratory markers in outpatients with human immunodeficiency virus infection.Impact of randomized antiretroviral therapy initiation on glucose metabolismCarotid artery intima-media thickness and HIV infection: traditional risk factors overshadow impact of protease inhibitor exposure.Clinical evaluation and management of metabolic and morphologic abnormalities associated with human immunodeficiency virus.Strategies for treating HIV-related lipodystrophy.Prevalence of hyperglycemia among adults with newly diagnosed HIV/AIDS in China.Cost analysis of pharmaceutical care provided to HIV-infected patients: an ambispective controlled study.Hyperglycemia enhances kidney cell injury in HIVAN through down-regulation of vitamin D receptorsIndinavir acutely inhibits insulin-stimulated glucose disposal in humans: a randomized, placebo-controlled study.The effect of Spirulina platensis versus soybean on insulin resistance in HIV-infected patients: a randomized pilot study.Atherosclerotic cardiovascular disease risk in the HAART-treated HIV-1 population.Cardiovascular disease and toxicities related to HIV infection and its therapies.Disorders of glucose metabolism in the context of human immunodeficiency virus infection.Nadir CD4+, religion, antiretroviral therapy, incidence of type 2 diabetes mellitus, and increasing rates of obesity among black Africans with HIV disease.Effect of antiretroviral drugs on the pharmacodynamics of gliclazide with respect to glucose-insulin homeostasis in animal models.Hormonal contraception and HIV-positive women: metabolic concerns and management strategiesEffects of once-daily darunavir/ritonavir versus atazanavir/ritonavir on insulin sensitivity in HIV-infected persons over 48 weeks: results of an exploratory substudy of METABOLIK, a phase 4, randomized trial.Influence of non-nucleoside reverse transcriptase inhibitors (efavirenz and nevirapine) on the pharmacodynamic activity of gliclazide in animal modelsMetabolic complications associated with antiretroviral therapy in HIV-infected and HIV-exposed uninfected paediatric patients.HIV medications: an update and review of metabolic complications.HIV1-viral protein R (Vpr) mutations: associated phenotypes and relevance for clinical pathologies.High prevalence of radiological vertebral fractures in HIV-infected males.O-linked N-acetylglucosaminylation of Sp1 inhibits the human immunodeficiency virus type 1 promoter.Impact of switching from lopinavir/ritonavir to boosted and un-boosted atazanavir on glucose metabolism: the ATAzanavir & GLUcose metabolism (ATAGLU) study.Discrimination of Patients With Different Serological Evolution of HIV and Co-Infection with HCV Using Metabolic Fingerprinting Based on FT-IR.Hyperlipidemia in HIV-positive patients receiving antiretrovirals.Prospective, intensive study of metabolic changes associated with 48 weeks of amprenavir-based antiretroviral therapy.Lipid changes in patients initiating efavirenz- and indinavir-based antiretroviral regimens.Coronary artery disease in HIV infected patients.Inaccurate glycosylated hemoglobin A1C measurements in human immunodeficiency virus-positive patients with diabetes mellitus.[Metabolic alterations in HIV-associated lipodystrophy syndrome].Enhanced glucagon-like peptide-1 (GLP-1) response to oral glucose in glucose-intolerant HIV-infected patients on antiretroviral therapy.Effect of antiretroviral therapy and hepatitis c co-infection on changes in lipid levels in HIV-Infected patients 48 weeks after initiation of therapy.Effectiveness and tolerability of oral administration of low-dose salmon oil to HIV patients with HAART-associated dyslipidemia.[Corporal fat distribution and lipidic and glicemic profiles of HIV-infected patients].
P2860
Q24617882-18F97AAC-FD90-4ED4-BA34-288654E63C31Q28473706-6409A29C-E315-4227-89B9-9B67F7DCEA17Q28729739-B9A55AF4-C896-4C25-8D03-04DC5DE26762Q33562238-C51B07AC-B8E0-43CA-B5E9-5ACB8CEBF72FQ33896762-C988E7E8-C4C4-472D-A686-8FF88D377632Q34034101-A32DE180-4F9C-4B3E-9EE5-5006628F4CEDQ34205448-5ECBF991-30E7-4457-A976-5E4829AE18B2Q34374679-CA88FB87-2358-4AF6-94A4-4C360FC4B572Q34461377-C7F2582F-422C-4E22-8BB1-E5468D339358Q34481623-6104EDF4-8212-4C8F-A9E2-C75BFADCB33FQ34581209-724311C9-AA8F-455D-B0F9-334ABDBA644CQ35102751-91310CD3-750C-41F9-8A5D-9BD1BB5E3968Q35141509-30FE6584-D8E9-4F3C-AD9E-5E216FCFE124Q35195035-4C74ED20-0627-45CF-B761-AD0D43CBC692Q35671049-546722D7-D7EE-4459-858E-02FBDA7AC48EQ36070094-12419BF8-166D-4A93-BD46-B8037BAEC31AQ36299974-44B56C0B-2969-4BBD-8F4E-BF8D43626B81Q36405647-8F06054E-3BEB-4C93-8C67-A5B296C8611BQ36444419-63AC2F07-5BB2-4B80-BCA9-BEC9B56EC08FQ36890380-9C780755-5BD7-4771-873E-D44FF375A5C7Q37202281-16EEF96B-5D20-45C5-BAD4-D12EAB1C5DDAQ37250997-A021DCFF-9B74-4A4A-9E85-25B4F601E13FQ37395532-6718478D-40EE-4D71-95BE-58DD64960A42Q37676229-E6487779-7EA3-4B58-854B-8F77399CC232Q37981602-280C25A8-59D3-41B5-BD1D-4428539EC602Q38855423-73222F80-9749-4F35-84BC-A65599AC7324Q39530457-2A82DEF1-6D5C-43B9-AD3E-9EBE44FE7600Q39887434-D74C2E49-FD86-4B40-AC6F-A282D6A8C407Q41166201-012FD000-DF6A-452C-AE1D-08DC67D39F00Q41930068-FF71144E-4FE9-47EC-AC80-070C9F4B1CE6Q43936404-0BC45DFE-80E5-40AA-BA83-F5A7F0949BD7Q44081426-C22AAFF8-3324-4712-8090-126FADB3A2EEQ44309075-3BF7CA13-D9DA-4A70-B3AE-DBBE30486EE9Q44435381-2513AC94-D58B-4BD9-9C72-C2A283C1E0E3Q44541007-9C28357F-82B0-4433-8862-78D43EF7E02CQ45099760-A1D3F110-FB2A-4A7A-B558-259E2B996E8DQ46419540-BE1B111C-E6E2-4526-9119-30FC73BBCF07Q46879484-41BD7D39-54D2-4BF0-8A39-74D065B1D6E8Q46879488-176BE99F-4E80-4E30-840E-B5BF622704C2Q51473140-435C7F5F-9ABC-49C8-BBA1-82D5916E4081
P2860
Disorders of glucose metabolism in patients infected with human immunodeficiency virus.
description
2000 nî lūn-bûn
@nan
2000 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած
@hyw
2000 թվականի նոյեմբերին հրատարակված գիտական հոդված
@hy
2000年の論文
@ja
2000年論文
@yue
2000年論文
@zh-hant
2000年論文
@zh-hk
2000年論文
@zh-mo
2000年論文
@zh-tw
2000年论文
@wuu
name
Disorders of glucose metabolism in patients infected with human immunodeficiency virus.
@ast
Disorders of glucose metabolism in patients infected with human immunodeficiency virus.
@en
Disorders of glucose metabolism in patients infected with human immunodeficiency virus.
@nl
type
label
Disorders of glucose metabolism in patients infected with human immunodeficiency virus.
@ast
Disorders of glucose metabolism in patients infected with human immunodeficiency virus.
@en
Disorders of glucose metabolism in patients infected with human immunodeficiency virus.
@nl
prefLabel
Disorders of glucose metabolism in patients infected with human immunodeficiency virus.
@ast
Disorders of glucose metabolism in patients infected with human immunodeficiency virus.
@en
Disorders of glucose metabolism in patients infected with human immunodeficiency virus.
@nl
P2860
P356
P1476
Disorders of glucose metabolism in patients infected with human immunodeficiency virus.
@en
P2093
P2860
P304
P356
10.1086/317491
P407
P577
2000-11-29T00:00:00Z